Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.64 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.51 |
| ▸ | FNTA | P49354 | 3/20 | 0.45 |
| ▸ | FNTB | P49356 | 3/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione SCHEMBL16739377 | 0.90 | PTGS1 (0.76) | PTGS1GSTK1NOD1FNTAFNTB | |
| Glutathione SCHEMBL16739379 | 0.90 | PTGS1 (0.76) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL20179354 | 0.90 | PTGS1 (0.65) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL28050255 | 0.88 | NOD1 (0.59) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL13585207 | 0.88 | NOD1 (0.59) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL13585280 | 0.88 | NOD1 (0.59) | PTGS1GSTK1NOD1FNTAFNTB | |
| Glutathione SCHEMBL17165667 | 0.87 | PTGS1 (0.74) | PTGS1GSTK1NOD1FNTAFNTB | |
| Glutathione SCHEMBL17165670 | 0.87 | PTGS1 (0.74) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL20179357 | 0.85 | PTGS1 (0.61) | PTGS1GSTK1NOD1FNTAFNTB | |
| SCHEMBL20179363 | 0.84 | PTGS1 (0.70) | PTGS1GSTK1NOD1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2019-11-21 | — | — | US | disclosed |
| WO-2018094278-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH GLUTATHIONE COMPOSITIONS | RENOVION, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | PTGS1 194/4885GSTK1 8/4885NOD1 1784/4885 |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | PTGS1 194/4885GSTK1 8/4885NOD1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.